Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

169

Enrollment

INDUSTRY

Sponsor class

Conditions

Bronchiolitis Obliterans
Chronic Rejection of Lung Transplant
Lung Transplant Rejection
Lung Transplant; Complications
Lung Transplant Failure and Rejection
Chronic Lung Allograft Dysfunction

Interventions

DRUG: Liposomal Cyclosporine A
DRUG: Standard of Care

Sponsor

Zambon SpA